$CLBT

CLBT Looks 26.6% Undervalued on GF Value™

Cellebrite DI Ltd (CLBT) announced its subsidiary achieved CMMC Level 2 certification. GF Value™ estimates CLBT is 26.6% undervalued at $12.01 vs. $16.36 intrinsic value. CLBT has a GF Score™ of 87, strong financials, and 11.2% 3-year revenue growth. Insiders sold $5.2M shares, while 5 gurus hold positions.

Original reporting
Published Sep 1, 2026, 1:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 5:14 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefTechnology
Primary signal
$CLBT
Bullish
medium confidence
Mentioned
$CLBT
Relevance
5/10
alphai data visualization · based on gurufocus.com
Decision brief

The 30-second read

$CLBTBullishLow
01

Why it matters

The article combines a new compliance certification with valuation commentary, offering limited actionable insight.

02

Market read

The certification news is modestly relevant; valuation discussion reinforces a potential buying case but lacks new material catalysts.

03

What to watch

Potential delays in contract negotiations and competition from larger defense IT providers.

Relevance 5/10Novelty 5/10Timing: today

Background

GuruFocus valuation metrics (GF Value, GF Score) are used to assess CLBT's undervaluation relative to its fundamentals.

Company-level read

Ticker impact

$CLBTBullishMedium confidence
Context

Cellebrite's subsidiary CFSI obtained CMMC Level 2 certification, a new compliance milestone that could enable future DoD contracts.

Expected impact

Potential modest upside as investors price in expanded addressable market.

Evidence & confidence

The news is a fresh corporate development but limited in scale; impact depends on future contract awards.

Market effects

Highlights growing importance of cybersecurity compliance for defense contractors.

U.S. defense and cybersecurity sectors may see modest interest.

Limited to firms seeking DoD contracts; not a broad market driver.

Counterpoint

Certification alone may not translate to contracts; revenue impact could be minimal.

Key entities

  • Cellebrite DI Ltd

    Provider of digital investigative solutions, ticker CLBT.

  • Cellebrite Federal Solutions Inc.

    Achieved CMMC Level 2 certification.

Related articles

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.